Baseline MRI predicts future attacks and disability in clinically isolated syndromes

Neurology

Volumn 67, Issue 6, 2006, Pages 968-972

  Tintore M ^a   Rovira, A ^a   Rio J ^a   Nos, C ^a   Grive E ^a   Tellez N ^a   Pelayo, R ^a   Comabella, M ^a   Sastre Garriga, J ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN RADIOGRAPHY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; BRAIN; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SYNDROME; TIME FACTORS;

EID: 33749013556     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000237354.10144.ec     Document Type: Article

References (25)

1. Tintore M, Rovira A, Rio J, et al. Are optic neuritis really more benign than other first attacks? Ann Neurol 2005;57:210-215.
2. Tintoré M, Rovira A, Brieva L, et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MRI criteria to predict conversion to CDMS. Mult Scler 2001;7:359-363.
3. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116:135-146.
4. O'Riordan JI, Thompson AJ, Kingsley DPE, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10 year follow-up. Brain 1998;121:495-503.
5. Brex PA, Ciccarelli O, Jonathon I, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164.
6. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology 1997;49:1404-1413.
7. Beck RW, Smith CH, Gal RL, et al. Optic Neuritis Study Group. Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004;61:1386-1389.
8. Tintore M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27-30.
9. Andersson M, Alvarez-Cermeño J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.
10. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
12. Tintore M, Rovira A, Martínez MJ, et al. Isolated demyelinating syndromes: comparison of different MRI criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000;21:702-706.
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol 1983;13:227-231.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
15. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone? Multiple Scler 2003;9:154-159.
16. Paolino E, Fainardi E, Ruppi P, et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:572-575.
17. Jacobs LD, Kaba SE, Miller CM, Priore RL, Brownscheidle CM. Correlation of clinical, MRI and CSF findings in optic neuritis. Ann Neurol 1997;41:392-398.
18. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2003;61:602-611.
19. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004;62:51-59.
20. Miller D, Barkhof F, Montalban X, Thompson AJ, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis and prognosis. Lancet Neurol 2005;4:281-288.
21. Bufill E, Blesa R, Galan I, Dean G. Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. J Neurol Neurosurg Psychiatry 1995;58:577-581.
22. McDonnell GV, Hawkins SA. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 1998;50:423-428.
23. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
24. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
25. PRIMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-1504.